Gender-differential effects on blood glucose levels between acarbose and metformin in Chinese patients with newly diagnosed type 2 diabetes: a sub-analysis of the MARCH trial

Endocrine journal

article

Jianxin Li¹  Weiping Jia³  Juming Lu⁴  Jing Liu⁵  Yuan Xu⁶  Zhaojun Yang⁷  Jing Li¹  Zhongyan Shan¹  Wenying Yang⁷  Jie Liu⁸  Haoming Tian⁹  Zhiguang Zhou^1,10  Qiuhe Ji^1,11  Jianping Weng^1,12 

[1] Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University;The Third People’s Hospital of Dalian (Dalian Third People’s Hospital Affiliated to Dalian Medical University);Shanghai Jiaotong University Affiliated Sixth People’s Hospital;Chinese People’s Liberation Army General Hospital;Gansu Provincial Hospital;Beijing Chao Yang Hospital;China-Japan Friendship Hospital;Shanxi Province People’s Hospital;West China Hospital, Sichuan University;Xiangya Second Hospital of Central South University;Xijing Hospital, Fourth Military Medical University;The Third Affiliated Hospital of Sun Yatsen University

关键词: Gender difference;    Diabetes;    Glucose;    Body weight;   

DOI  :  10.1507/endocrj.EJ20-0006

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

Using the data from the trial of Metformin and AcaRbose in Chinese as the initial Hypoglycemic treatment (MARCH), this study was performed to compare the differential effects of acarbose and metformin on glucose metabolism after stratification by gender. Six hundred and forty patients who had finished the whole 48-week follow-up were included. The reduction of haemoglobin A1c (HbA 1c ) was comparable between acarbose- and metformin-treated patients among either females or males, and it was also similar between males and females treated with either acarbose or metformin for 24 and 48 weeks. The dropping of fasting plasma glucose (FPG) in acarbose-treated females was significantly less than that in metformin-treated females at both 24 and 48 weeks. Furthermore, the decrease of 2-hour postprandial glucose (2hPPG) in acarbose-treated males was significantly greater than that in metformin-treated males at both 24 and 48 weeks. Multiple linear regression analysis showed that drug selection was an independent factor affecting the decrease of FPG in female patients while it independently influenced 2hPPG in males at week 24 and 48. The reductions of FPG and 2hPPG at week 24 and 48 were also significantly different between metformin-treated females and metformin-treated males although gender was not an independent regulating factor. Our study indicates that there might be gender-differential effects on FPG and 2hPPG reduction when the comparisons are made between acarbose and metformin treatments.

【 授权许可】

Unknown